VivoSim Labs Pivots to 3D Tissue Services; Receives $5M Milestone
VivoSim Labs, Inc. has undergone a significant strategic pivot, changing its name from a clinical-stage biotech to focus on providing pharmaceutical and biotechnology services using proprietary 3D human tissue models for drug testing. This shift followed the sale of its FXR program to Eli Lilly and Company in March 2025 for an upfront $10.0 million and potential milestones. The company recently received a $5.0 million milestone payment in July 2026 related to the FXR314 development. Despite this, both management and auditors have expressed substantial doubt about the company's ability to continue as a going concern, highlighting the risks of its new unproven business strategy and ongoing operating losses.
Key Highlights
- Company rebranded to VivoSim Labs, Inc. and shifted business model to 3D human tissue testing services.
- Sold FXR program to Eli Lilly for $10.0 million upfront and up to $50.0 million in potential milestones.
- Received a $5.0 million milestone payment in July 2026 for FXR314 development.
- Offers liver and intestinal toxicology insights using proprietary NAM models with 87.5% sensitivity and 100% specificity.
- Holds a broad intellectual property portfolio with over 160 patents and pending applications worldwide.
- Management and auditors express substantial doubt about ability to continue as a going concern.
- Faces risks including substantial operating losses, intense competition, and need for additional funding.
Price Impact
More from VIVS